Novartis Research Group Aims to Use NGS, Other Technologies to Develop Personalized Cancer Dx | GenomeWeb

Novartis is launching a research group that will use next-generation sequencing, proteomics, and other technology to develop diagnostics to stratify cancer patients into existing clinical trials, to identify new markers for future drug development, and to commercialize assays through its diagnostic group Genoptix.

The Next Generation Diagnostics group will include between 35 and 40 people, about half of whom will be recruited by the end of the year, and is aiming to have its first assays function in clinical trials within one year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.